Relationship between hepatitis <scp>B</scp> virus genotype <scp>B</scp> and <scp>C</scp> and response to interferon therapy in <scp>HBeAg</scp> positive chronic hepatitis <scp>B</scp> patients: A meta‐analysis

Kong, Lingna; Qin, Bo; Ma, Qing; Li, Lin; Yu, Yao

doi:10.1111/jgh.12559

Cited by 8 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there were small numbers of children with genotype A or D (mostly from Europe), or E (mostly from Africa). In adults, genotypes A and B have been associated with better response to interferon than genotypes C and D 17 – 20 whereas the latter-mentioned genotypes may be associated with more severe liver disease and higher HBV DNA levels compared with those with genotype B 18 . Furthermore, there are geographic differences in genotype-phenotype associations.…”

Section: Discussionmentioning

confidence: 99%

Children with Chronic Hepatitis B in the United States and Canada

Schwarz

Cloonan

Ling

et al. 2015

The Journal of Pediatrics

View full text Add to dashboard Cite

Objectives To test the hypothesis that children with chronic hepatitis B (CHB) living in the US and Canada would also have international origins and characteristic hepatitis B virus (HBV) genotypes and laboratory profiles. Study design Clinical characteristics of children enrolled in the HBRN were collected from 7 US and Canadian centers. Results Children (n=343) with an age range of 1.0 – 17.8 years were enrolled; 78% of the children were Asian, 55% were adopted and 97% had international origins with either the child or a parent born in one of 31 countries. The majority had hepatitis B virus (HBV) genotype B (43%) or C (32%), and the remainder had genotype A (5%), D (16%), E (4%), or multiple (<1%). Children with genotype B or C were Asian (98% and 96%), more consistently hepatitis B e antigen (HBeAg) positive (95% and 82%), had higher median HBV DNA levels (8.2 and 8.3 log10 IU/mL), and less frequently had elevated alanine aminotransferase values (43% and 57%) compared with children with other genotypes. The percentage of HBeAg positivity and of those with HBV DNA ≥6 log10 IU/mL declined with age. Conclusions The majority of children in the HBRN have HBV genotypes which reflect their international origins. Clinical and laboratory data differ substantially by patient age and HBV genotype. Use of these data can help drive the development of optimal strategies to manage and treat children with CHB.

show abstract

Section: Discussionmentioning

confidence: 99%

Children with Chronic Hepatitis B in the United States and Canada

Schwarz

Cloonan

Ling

et al. 2015

The Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…The HBV genotype is associated with the treatment response to peginterferon alfa therapy. Those with HBV genotype A or B showed a more favorable HBeAg response, HBsAg response, and virological response than those with HBV genotype C or D [108,220,251,252].…”

Section: Definition and Predictors Of Antiviral Treatment Responsementioning

confidence: 99%

KASL clinical practice guidelines for management of chronic hepatitis B

2019

Clin Mol Hepatol

184

107

View full text Add to dashboard Cite

Background and Aims Clinical practice guidelines for the management of chronic hepatitis B (CHB) were originally published in 2004 by the Korean Association for the Study of the Liver (KASL) in order to provide specific medical information regarding CHB that would facilitate treatment of infected patients. Other than an update on treatment of antiviral resistance in 2014, which is a partial revision, the guidelines for the treatment of CHB have been revised entirely three times in 2007, 2011, and 2015. The Asian-Pacific Association for the Study of the Liver (APASL), the European Association for the Study of the Liver (EASL), and the American Association for the Study of Liver KASL clinical practice guidelines for management of chronic hepatitis B Korean Association for the Study of the Liver (KASL) *

show abstract

“…100 In this study, HBsAg decline during treatment varied significantly according to HBV genotype (A and B more than C and D; p <0.001). In a meta-analysis of 15 studies, patients with genotype B infections had a better response to IFN than patients with genotype C. 101 These papers provided evidence for a more personalised approach for treatment of HBV with PEG-IFN, based on HBV genotype and HBsAg quantification.…”

Section: Interferon Treatment Outcomesmentioning

confidence: 99%

How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?

Rajoriya

Combet

Zoulim

et al. 2017

Journal of Hepatology

141

125

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection remains a global problem. Several HBV genotypes exist with different biology and geographical prevalence. Whilst the future aim of HBV treatment remains viral eradication, current treatment strategies aim to suppress the virus and prevent the progression of liver disease. Current strategies also involve identification of patients for treatment, namely those at risk of progressive liver disease. Identification of HBV genotype, HBV mutants and other predictive factors allow for tailoured treatments, and risk-surveillance pathways, such as hepatocellular cancer screening. In the future, these factors may enable stratification not only of treatment decisions, but also of patients at risk of higher relapse rates when current therapies are discontinued. Newer technologies, such as next-generation sequencing, to assess drug-resistant or immune escape variants and quasi-species heterogeneity in patients, may allow for more information-based treatment decisions between the clinician and the patient. This article serves to discuss how HBV genotypes and genetic variants impact not only upon the disease course and outcomes, but also current treatment strategies. Adopting a personalised genotypic approach may play a role in future strategies to combat the disease. Herein, we discuss new technologies that may allow more informed decision-making for response guided therapy in the battle against HBV.

show abstract

Relationship between hepatitis B virus genotype B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients: A meta‐analysis

Abstract: The results of the current meta-analysis indicate that HBV genotype B patients receiving interferon therapy respond better to treatment compared with genotype C patients, but this needs to be further examined.

Cited by 8 publications

References 32 publications

Children with Chronic Hepatitis B in the United States and Canada

Children with Chronic Hepatitis B in the United States and Canada

KASL clinical practice guidelines for management of chronic hepatitis B

How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?

Contact Info

Product

Resources

About